Edition:
India

Therapix Biosciences Ltd (TRPX.OQ)

TRPX.OQ on NASDAQ Stock Exchange Capital Market

5.40USD
8 Dec 2017
Change (% chg)

-- (--)
Prev Close
$5.40
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
5,456
52-wk High
$10.90
52-wk Low
$4.42

Summary

Name Age Since Current Position

Ascher Shmulewitz

61 2017 Chairman of the Board, Interim Chief Executive Officer

Josh Blacher

2017 Chief Financial Officer

Guy Goldin

43 2016 Vice President - Finance

Doron Ben Ami

53 2015 Vice President-Strategy

Adi Zuloff-Shani

47 2016 Vice President-Technologies

Ahmed Alimi

44 2015 Director

Mark Groussman

44 2017 Director

Tamar Kfir

2013 Director

Itzhak Kobrin

2013 Director

Abraham Meizler

65 2014 Director

Itamar Shalit

67 2005 Director

Stephen Siems

65 2016 Director

Eric So

41 2017 Director

Einat Zisman

51 2006 Director

Amit Berger

53 2014 External Director

Zohar Heiblum

60 2016 Independent Director

Yafit Stark

61 2015 Independent Director

Biographies

Name Description

Ascher Shmulewitz

Dr. Ascher Shmulewitz has been appointed Interim Chief Executive Officer, in addition to his role of Chairman of the Board, at Therapix Biosciences Ltd, effective November 2, 2017. Dr. Shmulewitz' work experience includes the following roles: Chairman of the Board at the Company (since January 8, 2014), Director at the Company (February 21, 2013-January 8, 2014), Founding Investor of the Company, Founder of and Investor in life science companies including NeoVision Corp., Labcoat Medical Ltd., Arteria Corp, Circulation Inc. and X-Cardia Inc., and led many of these companies to successful exits, including through merger and acquisition transactions, Co-Founder of Incumed Group, Medgenesis Partners Ltd and has held senior executive positions at Advanced Technology Laboratories Inc. (1988-1992). Dr. Shmulewitz holds a Doctorate of Medicine degree from The Technion – Israel Institute of Technology and a Doctorate of Science degree in Engineering from Tel Aviv University.

Josh Blacher

Mr. Josh Blacher has been appointed Chief Financial Officer at Therapix Biosciences Ltd effective May 3, 2017. His work experience includes the following roles: Chief Financial Officer at Galmed Pharmaceuticals, has held senior roles in licensing and investing at Teva-Pharmaceutical Industries Ltd, Portfolio Management at Deutsche Asset Management, has held Equity Research roles at Morgan Stanley and Mergers & Acquisitions role at Lehman Brothers. He holds a MBA degree in Finance from Columbia Business School.

Guy Goldin

Mr. Guy Goldin has been appointed Vice President - Finance at Therapix Biosciences Ltd effective April 1, 2016. Until this date, he will continue to serve as Chief Financial Officer at the Company, as he has since November 1, 2015. His work experience includes the following roles: Vice President – Finance at BSP Biological Signal Processing (from October 2012), Vice President – Finance at Petro Group Ltd (from September 2010) and Finance Director at Metis Capital Ltd (August 2007-May 2012). He holds a Bachelors degree in Accounting and Economics and a MBA degree, both from Tel Aviv University. He is a Certified Public Accountant.

Doron Ben Ami

Mr. Doron Jacob Ben Ami has been appointed Vice President-Strategy at Therapix Biosciences Ltd effective December 1, 2015. His work experience includes the following roles: Senior Consultant at Harel Consulting (from 2015), Founder and Chief Executive Officer of Triticum Ltd (from 2012), Associate Vice President and Managing Director-East Europe and Israel at Merck & Co. Inc (MSD) (2010-2015) and Chief Executive Officer at MSD Israel-Merck & Co. Inc (MSD) (2008-2010). He holds a Bachelor of Science degree in Physical Therapy from Ben Gurion University and a Masters degree in Health Systems Management from Tel Aviv University.

Adi Zuloff-Shani

Dr. Adi Zuloff-Shani has been appointed Vice President-Technologies at Therapix Biosciences Ltd effective February 8, 2016. Her work experience includes the following roles: Vice President-Development at Macrocure Ltd. (2012-2016) and Product Export and Head of New Initiatives at Macrocure Ltd. (2008-2012). She holds a Bachelor of Science degree in Biology, a Master of Science degree in Immunology and a Doctorate of Science degree in Immunology, all from Bar Ilan University.

Ahmed Alimi

Mr. Ahmed Alimi has been appointed Director at Therapix Biosciences Ltd effective June 10, 2015. He also holds Directorship in Vaxil-Bio Ltd. He holds a Bachelor of Business Administration degree, majoring in Finance, from Hamichlala Leminhal.

Mark Groussman

Mr. Mark Groussman has been appointed Director at Therapix Biosciences Ltd effective March 15, 2017. His work experience includes the following roles: President of Melechdavid Inc (since 2006), Investor in private and public companies, Director at American Strategic Minerals Corporation and Director at MusclePharm Corporation. He holds a Bachelor of Arts degree from George Washington University and a Masters degree in Real Estate Finance from New York University.

Tamar Kfir

Itzhak Kobrin

Abraham Meizler

Itamar Shalit

Dr. Itamar Shalit has served as Member of the Board of Directors of Nasvax Ltd since July 18, 2005. Dr. Shalit is Director of the Pediatric Infectious Disease Unit at the Schneider Children's Medical Center in Petah-Tikva. Formerly, he served as Director General of Schneider Children's Hospital, and as Director General of Carmel Hospital. Dr. Shalit is a senior lecturer at Sackler School of Medicine of Tel-Aviv University. He serves on numerous committees including many steering committees of Israel's Ministry of Health, and is the Acting Chairman for its Epidemics Management Team. Presently, Dr. Shalit is also Chairman of the Israeli Society for Infectious Diseases. He regularly participates in scientific meetings worldwide, and in 2002, he was awarded with the Certificate of Appreciation Declaration by the World Health Organization for the contribution, efforts and success in poliomyelitis eradication in Israel. Dr. Shalit won numerous grants from various agencies including global pharmaceutical companies. Dr. Shalit has published scientific books and chapters, and over 70 articles in medicinal journals worldwide. Dr. Shalit received his Master of Public Administration degree in Public Administration from Harvard University, and his Doctorate of Medicine degree in Medicine from Tel-Aviv University.

Stephen Siems

Mr. Stephen M. Siems has been appointed Director at Therapix Biosciences Ltd effective December 1, 2016. His work experience includes the following roles: Chief Executive Officer at RestroGenex Corporation (March 2014-January 2016) and Chief Executive Officer at BioSante Pharmaceuticals, Inc. (1998-2013). He holds a Bachelor of Science degree in Chemistry from City University of New York and a MBA degree from New York University.

Eric So

Mr. Eric How-Lun So has been appointed Director at Therapix Biosciences Ltd effective June 28, 2017. His work experience includes the following roles: Chief Legal Officer and Chief Corporate Development Officer at Mundo Inc, Vice-President, Corporate Strategy and General Counsel at Synergex Corporation (August 2006-September 2012), corporate, commercial and securities Lawyer at Torys LLP and Fraser Milner Casgrain LLP, Director at the Yee Hong Centre for Geriatric Care and Director at the Hong Fook Mental Health Foundation. He holds a Bachelor of Science degree from McGill University (Quebec, Canada) and a LLB degree from University of Windsor (Ontario, Canada).

Einat Zisman

Amit Berger

Mr. Amit Berger has been appointed External Director at Therapix Biosciences Ltd effective August 21, 2014. Mr. Berger's work experience includes a Chairman position at Enter Holdings 1 Ltd. between 2006 and 2009 and a Chief Executive Officer position at Dolphin 1 Investments Ltd. from 2009. Mr. Berger holds various Directorships at various companies. Mr. Berger holds a Bachelors degree in Economics from Tel Aviv University.

Zohar Heiblum

Mr. Zohar Heiblum has been appointed Independent Director at Therapix Biosciences Ltd effective August 26, 2016. Prior to this, he served as External Director at the Company (August 26, 2013-August 26, 2016). His work experience includes the following roles: Chairman of the Board at Z. Roth Industries Ltd (2013-2015), Managing Partner at Momentum Management (since 2001), Manager at Daniron Consultancy and Investments (from 1996) and Manager at Alvarion Ltd (2013-2014). He holds a Bachelor of Science degree in Industrial Engineering and Management Sciences and a MBA degree, both from Tel Aviv University.

Yafit Stark

Dr. Yafit Stark has been appointed Independent Director at Therapix Biosciences Ltd effective June 10, 2015. Her work experience includes the role of Vice President at Teva-Pharmaceutical Industries Ltd. Dr. Stark holds a Doctorate of Medicine degree in Pathology and a Post-Doctorate in Immune histopathology, both from Tel Aviv University.